Goldman Sachs
AMED

Goldman Sachs’s Amedisys AMED Stock Holding History

Goldman Sachs’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,000
Closed -$1.63M – 6043
2024
Q4 		$1.63M Buy
+18,000
New +$1.65M ﹤0.01% 4463
2023
Q4 		– Sell
-49,200
Closed -$4.6M – 5606
2023
Q3 		$4.6M Buy
+49,200
New +$4.55M ﹤0.01% 3056
2015
Q3 		– Sell
-54,700
Closed -$2.17M – 7260
2015
Q2 		$2.17M Buy
+54,700
New +$1.7M ﹤0.01% 3757
2013
Q4 		– Sell
-50,000
Closed -$861K – 6640
2013
Q3 		$861K Buy
+50,000
New +$742K ﹤0.01% 4720

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's AMED Position: Q3 2025 in Review

Goldman Sachs sold out of Amedisys (AMED) in Q3 2025, closing a stake of 242,944 shares — an estimated $23.9M sold.

Goldman Sachs first reported a position in AMED in Q2 2013 and held it in 47 quarters. The position peaked at $102M in Q2 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Goldman Sachs reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 242,944 Amedisys shares in Q3 2025, an estimated $23.9M.
  • Goldman Sachs first reported a position in Amedisys in Q2 2013 and held it in 47 quarters.
  • Goldman Sachs's Amedisys position peaked at $102M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.